PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis.

Abstract The American Joint Committee on Cancer (AJCC) released its 8th edition of tumor staging which is to be implemented in early 2018. The present study aimed to analyze the prognostic value of AJCC 8th edition Cancer Staging System in HER2-enriched breast cancer, on a retrospective cohort.
PMID
Related Publications

Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.

The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China.

Prognostic value of AJCC TNM Staging 7th edition in limited-stage small cell lung cancer: validation in 437 patients.

Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.

A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer.

Authors

Mayor MeshTerms
Keywords

AJCC cancer staging system

Breast cancer

HER2-enriched subtype

prognostic value

Journal Title anticancer research
Publication Year Start




PMID- 28739761
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer
      (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective
      Analysis.
PG  - 4615-4621
AB  - BACKGROUND/AIM: The American Joint Committee on Cancer (AJCC) released its 8th
      edition of tumor staging which is to be implemented in early 2018. The present
      study aimed to analyze the prognostic value of AJCC 8th edition Cancer Staging
      System in HER2-enriched breast cancer, on a retrospective cohort. PATIENTS AND
      METHODS: This study was a retrospective single-center study of HER2-enriched
      breast cancer cases diagnosed from January 2008 to December 2014.
      Clinicopathological features and follow up data including disease-free survival
      (DFS) and overall survival (OS) were analyzed to explore prognostic factors for
      disease outcome. We restaged patients based on the 8th edition of the AJCC cancer
      staging system and analyzed prognostic value of the Anatomic Stage Group and the 
      Prognostic Stage Group. RESULTS: The study enrolled 170 HER2-enriched subtype
      breast cancer patients with 5-year disease free survival (DFS) of 85.1% and
      5-year overall survival (OS) of 86.8%. Prognostic stages of 117 cases (68.8%)
      changed compared with anatomic stages, with 116 upstaged cases and 1 downstaged
      case. The Anatomic Stage Groups had a significant prognostic impact on DFS
      (chi2=16.752, p<0.001) and OS (chi2=25.038, p<0.001). The Prognostic Staging
      Groups had a significant prognostic impact on DFS (chi2=6.577, p=0.037) and OS
      (chi2=21.762, p<0.001). In the multivariate analysis, both stage groups were
      independent predictors of OS. CONCLUSION: Both Anatomic and Prognostic Stage
      Groups in the 8th edition of the AJCC breast cancer staging system had prognostic
      value in HER2-enriched subtype breast cancer. The Prognostic Stage system was a
      breakthrough on the basis of anatomic staging system.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Zhou, Bin
AU  - Zhou B
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
FAU - Xu, Ling
AU  - Xu L
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
FAU - Ye, Jingming
AU  - Ye J
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
FAU - Xin, Ling
AU  - Xin L
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
AD  - Cardiff China Medical Research Collaborative, Cardiff University School of
      Medicine, Cardiff, U.K.
FAU - Duan, Xuening
AU  - Duan X
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
FAU - Liu, Yinhua
AU  - Liu Y
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China
      [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/metabolism/*mortality/*pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
MH  - Retrospective Studies
OTO - NOTNLM
OT  - AJCC cancer staging system
OT  - Breast cancer
OT  - HER2-enriched subtype
OT  - prognostic value
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/05/19 [received]
PHST- 2017/06/06 [revised]
PHST- 2017/06/07 [accepted]
AID - 37/8/4615 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4615-4621.